藥品專利延長之爭議-論國外臨床試驗訖日之認定

Abstract

現代生技醫藥產業之發展高度仰賴專利制度，然因新藥上市前必須經過漫長且嚴格之法規審查與人體臨床試驗，導致專利有效期間大幅耗損。為彌補此一耗損，各國相繼引入專利權期間延長（Patent Term Extension, PTE）制度。然而，我國實務上針對國外試驗期間之「訖日」認定，主管機關即經濟部智慧財產局與司法實務間存在重大歧異。經濟部智慧財產局傾向採認國際醫藥法規協和會International Council for Harmonisation（下稱 ICH ）所規範定義之「試驗完成日」（Study Completion Date，最後一位受試者完成試驗之日期）而給予較短之專利延長期間；然司法實務近期多數見解認為應採認涵蓋數據分析與報告撰寫之「臨床試驗報告日」（Clinical Study Report Date）。 此見解衝突嚴重影響新藥開發藥廠對於專利懸崖（Patent Cliff）與營收損失之財務淨現值評估，進而損及法治國原則下之法律可預測性。 本文擬採取比較法學與文獻分析並行之研究方式。首先，溯源專利延長制度之歷史與法理基礎，並透過輝瑞（Pfizer）旗下之小分子藥物 Lipitor 與艾伯維（AbbVie）旗下之生物製劑 Humira 等實際案例，量化分析「專利懸崖」（Patent Cliff）對藥廠全球營收之毀滅性打擊，凸顯專利延長天數在商業實務上錙銖必較之鉅額財務價值 。其次，深入剖析並評論批判經濟部智慧財產局以「吸引外商來台進行臨床試驗」作為限縮國外試驗認定標準之政策理由。研究分析指出，真正影響跨國藥廠全球臨床試驗佈局與新藥引進時程之核心因素，在於我國「全民健康保險藥物給付項目及支付標準」之核價基準與市場准入機制，而非區區數月之專利延長差異 。經濟部智慧財產局之觀點在法學方法論上混淆了「權利補償」與「產業政策」之界線，在經濟實務上亦完全缺乏實證數據支持 。 透過廣泛且深入地比較美國、歐盟、韓國、日本等重要醫藥市場之法制設計與最新實務發展，本論文發現我國現行法正是滋生無數微觀日期認定爭議之根源 。為徹底解決此一制度僵局，本論文提出具體建議：於短期內，經濟部智慧財產局應立即修正專利權期間延長審查基準，採納臨床試驗報告完成日標準，以符合法律保留原則與平等原則 ；就長期法制發展而言，我國應推動專利法修法，研議引入之宏觀公式化計算模型，從根本上消除針對個別臨床試驗完成日期之爭訟，建立一個具備高度可預測性且能兼顧產業創新與公共利益之藥品專利延長制度。

The development of the modern biopharmaceutical industry relies heavily on the patent system. However, because new drugs must undergo lengthy and rigorous regulatory reviews and human clinical trials before marketing, the effective patent term is significantly eroded. To compensate for this loss, various countries have successively introduced the Patent Term Extension (PTE) system. Nevertheless, in Taiwan’s practice regarding the determination of the "end date" for foreign clinical trial periods, a major discrepancy exists between the competent authority—the Taiwan Intellectual Property Office (TIPO) of the Ministry of Economic Affairs—and judicial practice. TIPO tends to recognize the "Study Completion Date" (the date on which the last subject completed the trial) as defined by the International Council for Harmonisation (ICH), which grants a shorter extension period. Conversely, recent prevailing judicial opinions hold that the "Clinical Study Report (CSR) Date," which encompasses data analysis and report writing, should be adopted instead. This conflict of opinions severely impacts pharmaceutical developers' Net Present Value (NPV) assessments regarding patent cliffs and revenue losses, thereby undermining legal predictability under the principle of the rule of law. This thesis adopts a dual approach combining comparative law and literature analysis. First, it traces the historical and jurisprudential foundations of the patent extension system. Through empirical case studies of Pfizer's small-molecule drug Lipitor® and AbbVie's biologic drug Humira®, this thesis quantitatively analyzes the devastating impact of the "patent cliff" on global pharmaceutical revenues, thereby highlighting the immense financial value inherent in every single day of patent extension in commercial practice. Second, this thesis deeply analyzes and critiques TIPO’s policy rationale, which attempts to restrict the certification criteria for foreign trials under the guise of "attracting foreign companies to conduct clinical trials in Taiwan." The research indicates that the absolute core factor influencing multinational pharmaceutical companies' global clinical trial layouts and new drug introduction timelines lies in the pricing standards and market access mechanisms of Taiwan's National Health Insurance (NHI) drug reimbursement system, rather than a mere few months' difference in patent extensions. From the perspective of legal methodology, TIPO's viewpoint blurs the line between "rights compensation" and "industrial policy," and completely lacks empirical data support in economic practice. Through an extensive and in-depth comparison of the legal frameworks and recent practical developments in key pharmaceutical markets—including the United States, the European Union, South Korea, and Japan—this thesis finds that Taiwan's current statutory framework is the root cause of numerous microscopic disputes over date determination. To fundamentally resolve this institutional deadlock, this thesis proposes specific recommendations: in the short term, TIPO should immediately amend its Patent Term Extension Examination Guidelines in accordance with judicial rulings to fully adopt the Clinical Study Report completion date standard, thereby complying with the principle of legal reservation and the principle of equality. For long-term legal development, Taiwan should advance amendments to the Patent Act to explore the introduction of a macro formula-based calculation model. This would fundamentally eliminate litigation over the detailed dates of individual clinical trials, establishing a highly predictable pharmaceutical patent extension system that balances both industrial innovation and public interest.